Medicare+Choice — LLMpedia

Medicare+Choice
Name	Medicare+Choice
Introduced	1997
Repealed	2003 (replaced by Medicare Advantage)
Administering agency	Centers for Medicare & Medicaid Services
Related legislation	Balanced Budget Act of 1997
Predecessor	Fee-for-Service Medicare
Successor	Medicare Advantage

Contents

Medicare+Choice Medicare+Choice was a federal program established to expand options for Medicare beneficiaries through private plan enrollment, created by the Balanced Budget Act of 1997 and administered by the Centers for Medicare & Medicaid Services. It allowed integration of private health maintenance organizations and preferred provider organizations into the Medicare framework, intending to influence costs and access amid debates involving Congressional Budget Office, Office of Management and Budget, and stakeholders such as AARP, American Hospital Association, and Blue Cross Blue Shield Association. The program served as a bridge between traditional HMO models and later reforms culminating in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Background and enactment

The Balanced Budget Act of 1997, driven by policymakers including members of the United States Congress and influenced by analyses from the Congressional Budget Office and Medicare Payment Advisory Commission, enacted Medicare+Choice to respond to trends in managed care exemplified by organizations like Kaiser Permanente, Humana, Aetna, and CIGNA. Debates referenced fiscal episodes such as the 1990s federal budget deficit and involved advocacy from American Medical Association, National Association of Insurance Commissioners, and UnitedHealthcare. The law followed earlier experiments like the Medicare Risk Contracting Program and pilot initiatives in states such as California, New York, and Texas. Stakeholders cited comparative models including the Veterans Health Administration and international systems like National Health Service during legislative hearings presided by committees of the House of Representatives and the United States Senate.

Medicare+Choice encompassed plan types operated by entities such as HMOs, PPOs, PFFS operators, and Medical Savings Account-linked arrangements promoted by insurers like Blue Cross Blue Shield, Aetna, CIGNA, Humana, and regional plans including Kaiser Permanente. Benefit design referenced preventive services endorsed by agencies such as the U.S. Preventive Services Task Force and prescription coverage debates later addressed by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Plans negotiated provider networks including hospitals like Mayo Clinic, Cleveland Clinic, and systems such as Johns Hopkins Medicine while aligning with standards from the Joint Commission and accreditation by organizations like National Committee for Quality Assurance. Cost-sharing, copayments, and supplemental benefits mirrored trends in employer-sponsored plans like those from General Motors and Walmart.

Enrollment procedures interfaced with systems run by the Social Security Administration and Centers for Medicare & Medicaid Services, relying on beneficiary outreach from advocacy groups including AARP and enrollment brokers like Medicare Rights Center. Eligibility criteria tracked Part A and Part B entitlements influenced by rules from the Social Security Act and interactions with programs such as Medicaid in states like California, Florida, and Illinois. Enrollment trends were analyzed in reports by Government Accountability Office, think tanks such as the Urban Institute and Kaiser Family Foundation, and academic centers at Harvard School of Public Health, Johns Hopkins Bloomberg School of Public Health, and Yale School of Medicine.

Payment structures for Medicare+Choice drew on methodologies developed by the Health Care Financing Administration (predecessor to Centers for Medicare & Medicaid Services) and actuarial input from firms and institutions including Deloitte, PricewaterhouseCoopers, and university researchers at University of Michigan. Rate-setting used benchmarks from traditional Medicare fee-for-service reimbursements and relied on risk adjustment concepts developed in collaboration with researchers affiliated with Harvard Medical School and the RAND Corporation. Financing debates referenced federal budget analyses by the Congressional Budget Office and fiscal oversight by the Office of Management and Budget, with legal challenges touching courts like the United States Court of Appeals for the District of Columbia Circuit.

Evaluations by the Government Accountability Office, Medicare Payment Advisory Commission, and research from the Kaiser Family Foundation assessed effects on enrollment, cost growth, service utilization, and quality measures defined by National Committee for Quality Assurance and the Agency for Healthcare Research and Quality. Studies in journals such as Health Affairs, New England Journal of Medicine, and The Lancet compared outcomes across providers including Mayo Clinic and academic centers like Stanford University School of Medicine. Analyses highlighted regional variation in plan availability in markets such as Los Angeles, Chicago, Houston (TX), and Miami, and implications for rural areas exemplified by Iowa and Montana. Policy debates involved stakeholders like American Hospital Association, American Medical Association, and consumer advocates including Families USA.

Legislative change under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 rebranded and restructured Medicare+Choice into Medicare Advantage, affecting insurers such as Aetna, UnitedHealthcare, Humana, and plan sponsors like Blue Cross Blue Shield. Implementation engaged the Centers for Medicare & Medicaid Services and led to policy analyses by the Congressional Budget Office and Medicare Payment Advisory Commission, while subsequent litigation and administrative guidance involved the United States Department of Health and Human Services and oversight from the HHS OIG. The transition shaped later reforms affecting prescription drug coverage under Medicare Part D and continued interaction with state regulators like the New York State Department of Financial Services and market participants including Kaiser Permanente.